How Is Silent Ovarian Cancer Detected?

Ovarian cancer is called silent because it produces no specific early symptoms. Bloating, pelvic discomfort, frequent urination and early satiety are the four most commonly reported early indicators but all four are easily attributed to gut or urinary conditions. Most cases in India are diagnosed at Stage 3 or Stage 4. Detection before symptoms appear happens through incidental ultrasound findings, CA-125 testing in high-risk women and surveillance in confirmed BRCA1 or BRCA2 mutation carriers.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India,
“Ovarian cancer doesn’t announce itself. The women who get diagnosed early are almost always those in a surveillance programme or those whose general physician investigated persistent vague symptoms rather than treating them empirically.”

Detection relies on imaging, tumour markers and structured surveillance in high-risk women rather than population-wide screening which has not shown benefit in average-risk populations.

• Pelvic Ultrasound: Transvaginal ultrasound is the primary imaging tool for detecting adnexal masses and ovarian cancer treatment assessment at KIMS Hospital, Bangalore begins with transvaginal ultrasound combined with CA-125 for any woman presenting with persistent pelvic symptoms or an incidental adnexal finding on imaging.
• CA-125 Tumour Marker: CA-125 is elevated in most epithelial ovarian cancers but is not specific enough for population screening because it is also elevated in endometriosis, fibroids and pelvic inflammatory disease, making it most useful in combination with ultrasound findings rather than as a standalone test.
• BRCA Surveillance Protocol: Confirmed BRCA1 or BRCA2 mutation carriers who have not had risk-reducing salpingo-oophorectomy are offered six-monthly transvaginal ultrasound and CA-125 testing from age 30 to 35, recognising this surveillance has limitations but providing structured monitoring until preventive surgery is performed.
• Incidental Detection: A significant proportion of early ovarian cancers are detected incidentally on ultrasound ordered for an unrelated reason, underscoring the clinical value of investigating persistent non-specific pelvic or abdominal symptoms with imaging rather than empirical treatment.

No population-wide screening tool has demonstrated mortality benefit for ovarian cancer in average-risk women. Surveillance is reserved for confirmed high-risk individuals.

Structured ovarian cancer surveillance is clinically indicated in specific high-risk groups rather than recommended broadly.

• BRCA1 and BRCA2 Carriers: BRCA1 carriers face a 39 to 46 percent lifetime ovarian cancer risk and BRCA2 carriers face 12 to 20 percent and robotic cancer surgery or laparoscopic risk-reducing bilateral salpingo-oophorectomy between ages 35 and 40 for BRCA1 and 40 to 45 for BRCA2 remains the most effective intervention to reduce this risk.
• Strong Family History: Women with two or more first-degree relatives with ovarian or breast cancer, particularly diagnosed before age 50, warrant genetic counselling and BRCA testing before any surveillance programme is initiated rather than empirical surveillance without mutation confirmation.
• Lynch Syndrome Carriers: Lynch syndrome is associated with an 8 to 10 percent lifetime ovarian cancer risk and annual gynaecological review with transvaginal ultrasound is recommended from age 30 to 35 in confirmed carriers as part of the broader Lynch syndrome surveillance protocol.
• Persistent Vague Symptoms: Any woman over 50 with bloating, pelvic discomfort, early satiety or urinary frequency persisting for more than three weeks without a clear cause warrants immediate transvaginal ultrasound and CA-125 rather than empirical management for irritable bowel or urinary tract symptoms.

Early ovarian cancer detected through surveillance is surgically curable and for more on how specialist second opinions change cancer outcomes, our blog on second opinion covers this in detail.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to ovarian cancer surgery including cytoreductive surgery and HIPEC at KIMS Hospital, Bangalore. He heads Oncology Services across Karnataka with originator credits for RABIT, MIND and L-VEIL techniques and over 25 published clinical studies. Patients with ovarian masses, high-risk genetic profiles or ovarian cancer diagnoses are seen here with every case reviewed through tumour board. Call +91 8104310753 to book your consultation.

References

1. 1. National Cancer Institute — Ovarian Cancer Screening
   2. World Health Organization — Ovarian Cancer

• Disclaimer: The information shared in this content is for educational purposes and not for promotional use.